NCT02581982View on ClinicalTrials.gov

Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 6, 2016

Primary Completion Date

May 11, 2021

Study Completion Date

December 19, 2022

Conditions
Transitional Cell Carcinoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Paclitaxel

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

27157

Wake Forest University Health Sciences, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT02581982 - Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer | Biotech Hunter | Biotech Hunter